<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Atai Life Sciences Bv — News on 6ix</title>
    <link>https://6ix.com/company/atai-life-sciences-bv</link>
    <description>Latest news and press releases for Atai Life Sciences Bv on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 27 Apr 2026 08:05:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/atai-life-sciences-bv" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835491378dffbe2df0e418e.webp</url>
      <title>Atai Life Sciences Bv</title>
      <link>https://6ix.com/company/atai-life-sciences-bv</link>
    </image>
    <item>
      <title>AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-and-psypan-receive-a-silver-award-in-2026-patient-participant-index-reflecting-ongoing-commitment-to-participant-informed-research</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-and-psypan-receive-a-silver-award-in-2026-patient-participant-index-reflecting-ongoing-commitment-to-participant-informed-research</guid>
      <pubDate>Mon, 27 Apr 2026 08:05:00 GMT</pubDate>
      <description>NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced it has received the Silver Award in OVID Health’s 2026 Patient Participant Index (PPI), in collaboration with the Psychedelic Participant Advocacy Network (PsyPAN), in recognition of their joint efforts to strengthen p</description>
    </item>
    <item>
      <title>AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-announces-additional-phase-2a-results-for-emp-01-oral-r-mdma-showing-large-and-consistent-improvements-in-social-anxiety-disorder</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-announces-additional-phase-2a-results-for-emp-01-oral-r-mdma-showing-large-and-consistent-improvements-in-social-anxiety-disorder</guid>
      <pubDate>Wed, 22 Apr 2026 10:00:00 GMT</pubDate>
      <description>EMP-01 demonstrated a large, clinically meaningful reduction in patient-reported SAD symptoms at Day 43: placebo-adjusted LSMD -11.5 points (p=0.002) on SPIN; placebo-adjusted LSMD -15.6 points (p=0.004) on SAFE - a 38% and 32% reduction, respectivelyPatient-perceived global improvement: 49% PGI-C responders at Day 43 compared to 12% on placeboNo severe or serious adverse events NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-</description>
    </item>
    <item>
      <title>BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/bpl-003-demonstrates-rapid-and-durable-antidepressant-effects-in-treatment-resistant-depression-phase-2a-data-published-in-journal-of-psychopharmacology-phase-3-program-on-track-for-q2-2026-initiation</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/bpl-003-demonstrates-rapid-and-durable-antidepressant-effects-in-treatment-resistant-depression-phase-2a-data-published-in-journal-of-psychopharmacology-phase-3-program-on-track-for-q2-2026-initiation</guid>
      <pubDate>Tue, 17 Mar 2026 10:00:00 GMT</pubDate>
      <description>NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the peer-reviewed publication of results from its ongoing four-part Phase 2a study (NCT05660642) evaluating BPL-003 (mebufotenin benzoate nasal spray) in patients with treatment-resistant depression (TRD). Published in</description>
    </item>
    <item>
      <title>BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/bpl-003-phase-3-program-initiation-on-track-for-q2-2026-following-successful-fda-end-of-phase-2-meeting-ataibeckley-highlights-key-pipeline-milestones-at-2026-investor-day</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/bpl-003-phase-3-program-initiation-on-track-for-q2-2026-following-successful-fda-end-of-phase-2-meeting-ataibeckley-highlights-key-pipeline-milestones-at-2026-investor-day</guid>
      <pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
      <description>BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway reaffirmed through</description>
    </item>
    <item>
      <title>AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-and-clinical-update-15</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-and-clinical-update-15</guid>
      <pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
      <description>Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with</description>
    </item>
    <item>
      <title>AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-announces-successful-end-of-phase-2-meeting-for-bpl-003-in-treatment-resistant-depression</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-announces-successful-end-of-phase-2-meeting-for-bpl-003-in-treatment-resistant-depression</guid>
      <pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
      <description>Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosingPhase 3</description>
    </item>
    <item>
      <title>AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-announces-positive-topline-results-from-an-exploratory-phase-2a-trial-of-emp-01-oral-r-mdma-in-social-anxiety-disorder</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-announces-positive-topline-results-from-an-exploratory-phase-2a-trial-of-emp-01-oral-r-mdma-in-social-anxiety-disorder</guid>
      <pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
      <description>EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profileEMP-01</description>
    </item>
    <item>
      <title>AtaiBeckley To Host Virtual Investor Day on March 6, 2026</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-to-host-virtual-investor-day-on-march-6-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-to-host-virtual-investor-day-on-march-6-2026</guid>
      <pubDate>Fri, 20 Feb 2026 05:00:00 GMT</pubDate>
      <description>NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission</description>
    </item>
    <item>
      <title>AtaiBeckley Appoints Michael Faerm as Chief Financial Officer</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-appoints-michael-faerm-as-chief-financial-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-appoints-michael-faerm-as-chief-financial-officer</guid>
      <pubDate>Thu, 19 Feb 2026 05:00:00 GMT</pubDate>
      <description>NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a</description>
    </item>
    <item>
      <title>AtaiBeckley To Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-participate-upcoming-investor-conferences-120000651</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-participate-upcoming-investor-conferences-120000651</guid>
      <pubDate>Tue, 17 Feb 2026 12:00:00 GMT</pubDate>
      <description>NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Jason Awe, Ph.D., Vice President of Investor Relations, will participate in fireside chats and host one-on-one meetings at the following invest</description>
    </item>
    <item>
      <title>AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-participates-64th-annual-acnp-meeting-two-scientific-poster-presentations</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-participates-64th-annual-acnp-meeting-two-scientific-poster-presentations</guid>
      <pubDate>Fri, 16 Jan 2026 05:00:00 GMT</pubDate>
      <description>NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission</description>
    </item>
    <item>
      <title>AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-provides-update-and-outlook-2026-ahead-jp-morgan-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-provides-update-and-outlook-2026-ahead-jp-morgan-healthcare-conference</guid>
      <pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
      <description>NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a</description>
    </item>
    <item>
      <title>AtaiBeckley Completes Redomiciliation to the United States</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-completes-redomiciliation-united-states-2025-12-31</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-completes-redomiciliation-united-states-2025-12-31</guid>
      <pubDate>Tue, 30 Dec 2025 05:00:00 GMT</pubDate>
      <description>NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a</description>
    </item>
    <item>
      <title>AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-added-nasdaq-biotechnology-index-120000854</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-added-nasdaq-biotechnology-index-120000854</guid>
      <pubDate>Tue, 23 Dec 2025 12:00:00 GMT</pubDate>
      <description>NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced its common stock has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025. “2025 has been a defining year for AtaiBeckley, marked b</description>
    </item>
    <item>
      <title>AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-announces-new-us-patent-granted-emp-01-strengthening-intellectual</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-announces-new-us-patent-granted-emp-01-strengthening-intellectual</guid>
      <pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
      <description>NEW YORK and AMSTERDAM, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage</description>
    </item>
    <item>
      <title>Enhanced Fortifies Executive Leadership Team &amp; Board of Directors</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/enhanced-fortifies-executive-leadership-team-and-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/enhanced-fortifies-executive-leadership-team-and-board-of-directors</guid>
      <pubDate>Thu, 20 Nov 2025 00:32:00 GMT</pubDate>
      <description>Enhanced, the elite sports competition and performance products company committed to giving athletes and people alike the ability to optimize their health, performance and recovery, today announced that it has fortified its executive leadership team and its board of directors.</description>
    </item>
    <item>
      <title>AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-participate-jefferies-global-healthcare-conference-london-2025-11-13</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-participate-jefferies-global-healthcare-conference-london-2025-11-13</guid>
      <pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
      <description>NEW YORK and AMSTERDAM, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical</description>
    </item>
    <item>
      <title>AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-reports-third-quarter-2025-financial-results-and-recent-corporate</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-reports-third-quarter-2025-financial-results-and-recent-corporate</guid>
      <pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
      <description>AtaiBeckley solidifies position as a global leader in transformative mental health therapies with a short psychedelic duration BPL-003 (mebufotenin benzoate</description>
    </item>
    <item>
      <title>AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-announces-positive-topline-data-phase-2b-open-label-extension-study-bpl</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/ataibeckley-announces-positive-topline-data-phase-2b-open-label-extension-study-bpl</guid>
      <pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
      <description>A 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 12 mg, 8 mg or 0.3 mg dose in the core study of the Phase</description>
    </item>
    <item>
      <title>atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies</title>
      <link>https://6ix.com/company/atai-life-sciences-bv/news/atai-life-sciences-and-beckley-psytech-announce-successful-completion-their-strategic</link>
      <guid isPermaLink="true">https://6ix.com/company/atai-life-sciences-bv/news/atai-life-sciences-and-beckley-psytech-announce-successful-completion-their-strategic</guid>
      <pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
      <description>atai Life Sciences’ shareholders voted to approve the strategic combination with Beckley Psytech Limited and the corporate redomiciliation at the</description>
    </item>
  </channel>
</rss>